ATPC vs. LFMD, SBC, VMD, AIRS, TOI, EUDA, DCGO, CORBF, XGN, and SERA
Should you be buying Agape ATP stock or one of its competitors? The main competitors of Agape ATP include LifeMD (LFMD), SBC Medical Group (SBC), Viemed Healthcare (VMD), AirSculpt Technologies (AIRS), Oncology Institute (TOI), EUDA Health (EUDA), DocGo (DCGO), Global Cord Blood (CORBF), Exagen (XGN), and Sera Prognostics (SERA). These companies are all part of the "healthcare" industry.
Agape ATP vs.
Agape ATP (NASDAQ:ATPC) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
LifeMD received 40 more outperform votes than Agape ATP when rated by MarketBeat users.
LifeMD has a net margin of -12.06% compared to Agape ATP's net margin of -194.09%. LifeMD's return on equity of 0.00% beat Agape ATP's return on equity.
In the previous week, Agape ATP had 1 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for Agape ATP and 1 mentions for LifeMD. LifeMD's average media sentiment score of 0.94 beat Agape ATP's score of -0.47 indicating that LifeMD is being referred to more favorably in the news media.
Agape ATP has a beta of -0.55, indicating that its share price is 155% less volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.
0.0% of Agape ATP shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 9.7% of Agape ATP shares are owned by insiders. Comparatively, 16.0% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Agape ATP has higher earnings, but lower revenue than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than Agape ATP, indicating that it is currently the more affordable of the two stocks.
LifeMD has a consensus target price of $11.00, indicating a potential upside of 2.14%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Agape ATP.
Summary
LifeMD beats Agape ATP on 14 of the 18 factors compared between the two stocks.
Get Agape ATP News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATPC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agape ATP Competitors List
Related Companies and Tools
This page (NASDAQ:ATPC) was last updated on 5/22/2025 by MarketBeat.com Staff
